Abstract
Objective To investigate the clinical efficacy of ganciclovir (GCV) in the treatment of children with infectious mononucleosis (IM) and to detect the GCV' s influence on EB virus specific antibodies (VCA-IgM).Methods Sixty children with IM was collected from Qingbaijiang people' s hospital from January 2011 to January 2014.The patients were divided into treatment group and control group randomly.Patients in treatment group were given GCV,patients in control group were given IFN-α as treatment.The clinical symptoms improved,treatment efficiency,VCA-IgM and side effect were tested and compared between these two groups.Results The mean antipyretic time and mean term of sore throat relief was 3.57 d ± 1.24 d and 4.76 d ± 1.35 d respectively in treatment group,which were significantly shorter than the time in control 4.73d ± 1.36 d and 6.22d ± 1.75d,respectively.The effective rate of treatment group was significantly higher than that of control group 50.0% vs 26.7%.Three months after treatment,the positive rate of EBv-VCA-IgM in treatment group was significantly lower than that in control group 13.3% vs 53.3%.No severe side effect was observed in treatment group.Conclusions GCV is effective in treating children with IM.GCA can decrease EBv-VCA-IgM effectively. Key words: Children with infectious mononucleosis; EB virus ; Ganciclovir
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.